Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31591048 | 1.00 | PNMT (0.48) | PNMTADRA2ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL29113503 | 0.89 | PNMT (0.47) | PNMTADRA2ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL30612413 | 0.89 | PNMT (0.47) | PNMTADRA2ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL17797682 | 0.86 | MEN1 (0.44) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL21526447 | 0.82 | DPP7 (0.41) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL7513826 | 0.81 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL27035115 | 0.76 | LMNA (0.44) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL30768129 | 0.76 | LMNA (0.44) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL17797589 | 0.75 | PNMT (0.47) | PNMTADRA2A | |
| SCHEMBL30612409 | 0.75 | AKR1C3 (0.45) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | PNMT 1213/4885ADRA2A 2431/4885CHRNB4 3309/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | PNMT 821/4885ADRA2A 628/4885CHRNB4 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.